UCL Institute of Ophthalmology


IoO Guest Lecture

13 September 2022, 2:30 pm–3:30 pm

Brian Hafler

Speaker: Brian P. Hafler, Assistant Professor of Ophthalmology and Pathology at Yale School of Medicine.

This event is free.

Event Information

Open to

UCL staff | UCL students






IoO Events


IoO Lecture theatre
11-43 Bath Street London

Title: “Topological analysis of single-cell hierarchy reveals inflammatory glial landscape of macular degeneration”

This is a hybrid event. If you wish to attend in person please turn up on the day. If you wish to attend online please follow the link below on the day of the event. If you have any queries please email ioo.events@ucl.ac.uk 

MS Teams Link

About the Speaker

Brian Hafler

Assistant Professor of Ophthalmology and Pathology Yale School of Medicine at UCL Institute of Ophthalmology

After graduating magna cum laude from Princeton University, Dr. Hafler earned his MD/PhD from Harvard Medical School and completed a postdoctoral fellowship funded by the Howard Hughes Medical Institute in Connie Cepko's laboratory at Harvard. He completed an ophthalmology residency at Yale School of Medicine/Yale-New Haven Hospital and a fellowship in retina at Mass. Eye and Ear as a Heed Fellow where he specialized in Inherited Retinal Degenerations. Following his fellowship, he received a K08 Clinical Scientist Development Award from the NIH and joined the faculty at Harvard Medical School where he served on Mass. Eye and Ear’s Retina Service and in the Emergency and Trauma Eye Care Department. He has a laboratory in the Department of Ophthalmology in the Yale School of Medicine where he recently generated the first single-cell human retinal transcriptomic atlas and identified the cell types driving macular degeneration. He recently received the American Society for Clinical Investigation Young Physician Scientist Award, the Thome Memorial Foundation Award for AMD Research, and was named the William R. Orthwein, Jr. ’38 Yale Scholar. He studies macular degeneration and glaucoma using single-cell transcriptomics to identify novel therapeutic approaches.

More about Brian Hafler